InnoMed PredTox is one of two main research initiatives jointly funded under the name of InnoMed – Innovative Medicines for Europe

InnoMed is coordinated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), a body representing the research-based pharmaceutical industries and biotech SMEs operating in Europe. It is part funded by the European Commission Life Sciences, Genomics and Biotechnology for Health Priority (Ref. LSHB-CT-2005-518170) with a grant of €8M.

While both InnoMed initiatives are aimed at reducing key bottlenecks in the R&D; process, AddNeuroMed focused on identifying new biomarkers for Alzheimer’s dementia, whereas InnoMed PredTox is searching for markers to predict the toxicity of drug candidates.

Innomen PredTox key facts:

• Toxicogenomics (drug development)
• Assessing the value of combining results from omics technologies together with the results from more conventional toxicology methods for more informed decision making in preclinical safety evaluation
• 19 partners (14 pharma companies, 3 universities, 2 technology providers)